Adalimumab Interpretation
Use
The test is useful for therapeutic drug monitoring of adalimumab (ADL), particularly in cases of loss of response or hypersensitivity reactions. It aids in the evaluation of patients for secondary loss of response, primary nonresponse, reintroduction after a drug holiday, and monitoring during therapy such as in inflammatory bowel disease or autoimmune conditions. Monitoring can assist in distinguishing between pharmacokinetic failure and immunogenicity, enabling appropriate adjustments like dose escalation or switching therapies, thereby improving treatment cost-effectiveness and patient outcomes.
Special Instructions
This test is not orderable independently and must be ordered as part of a profile. For more information, see the ADALP / Adalimumab Quantitative with Antibody, Serum test. Blood draws for therapeutic drug monitoring should ideally occur at trough levels, immediately before the next dose of medication. Patients should refrain from biotin supplements at least 12 hours before sample collection to prevent interference.
Limitations
The test cannot distinguish between the reference product (Humira) and its biosimilars due to the shared primary amino acid sequence. Anti-drug antibodies (ADA) formation may influence drug levels and efficacy, being dependent on assay sensitivity and drug tolerance. Possible interference from ADL in serum can result in underestimated ATA titres. Testing is best performed immediately before the next ADL dose.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 77202-0
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided
Container
Special Container: None noted
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 28 days |
| Frozen | 28 days |